Hereditary Cancer in Clinical PracticeGenetic & Genomic MedicinePeer-reviewed journal article
Validation of a guidelines-based digital tool to assess the need for germline cancer genetic testing
Callan D. Russell, Ashley Daley, Durand R. Van Arnem, Andi Hila, Kiley J. Johnson, Jill N. Davies, Hanah S. Cytron, Kaylene J. Ready, Cary M. Armstrong, Mark E. Sylvester, Colleen A. CaleshuiD
Abstract
PurposeEfficient and scalable solutions are needed to identify patients who qualify for germline cancer genetic testing. We evaluated the clinical validity of a brief, patient-administered hereditary cancer risk assessment digital tool programmed to assess if patients meet criteria for germline genetic testing, based on personal and family history, and in line with national guidelines. MethodsWe applied the tool to cases seen in a nationwide telehealth genetic counseling practice. Validity of the tool was evaluated by comparing the tools assessment to that of the genetic counselor who saw the patient. Patients histories were extracted from genetic counselor-collected pedigrees and input into the tool by the research team to model how a patient would complete the tool. We also validated the tools assessment of which specific aspects of the personal and family history met criteria for genetic testing. ResultsOf the 152 cases (80% ((121/152)) female, mean age 52.3), 56% (85/152) had a personal history of cancer and 66% (99/152) met genetic testing criteria. The tool and genetic counselor agreed in 96% (146/152) of cases. Most disagreements (4/6; 67%) occurred because the GCs assessment relied on details the tool was not programmed to collect since patients typically dont have access to the relevant information (pathology details, risk models). We also found complete agreement between the tool and research team on which specific aspects of the patients history met criteria for genetic testing. ConclusionWe observed a high level of agreement with genetic counselor assessments, affirming the tools clinical validity in identifying individuals for hereditary cancer predisposition testing and its potential for increasing access to hereditary cancer risk assessment.
- organism: human
- assay: electronic health records
- research focus: benchmarking
- approach: statistical model
- Citations
- 5
- FWCI
- 1.33
- Field percentile
- top 20%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Title: A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2): study protocol
Evelyn Mastaglio, Brian Lee Egleston, … Angela R. Bradbury·BMC CancerPeer-reviewed·Jul 31, 2026
- BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial
Bethany Torr, Christopher Iain Jones, … Clare Turnbull·British Journal of CancerPeer-reviewed·Sep 30, 2024
- A Randomized Non-Inferiority Trial of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eREACH2)
Kimberley T. Lee, Brian Lee Egleston, … eREACH2 Group·Journal of Clinical OncologyPeer-reviewed·May 27, 2026
- Genetic testing in cancer: a systematic review of patient reported measures
Kelsie Raspin, Daisy Nowakowski, … Jessica K. Roydhouse·medRxiv·Jul 7, 2025
- Clinical criteria for genetic testing in pediatric oncology show a low specificity and miss every 4th child carrying a cancer predisposition
Ulrike Anne Friedrich, Marc Bienias, … Franziska Auer·medRxiv·Oct 22, 2022
- What tools do men need to make an informed decision about germline genetic testing for prostate cancer? A qualitative and survey study
Kelsie Raspin, Larissa Bartlett, … Joanne L. Dickinson·medRxiv·May 7, 2026